am pleased to have Northern Air partner with Inflamax Research to provide the best in Environmental Control Systems and importantly to keep them in top operation at all times,” says Dr. Salapatek, President and CSO Inflamax Research. “We have worked together on many projects in the past with Northern Air and are delighted to work with them again. This alliance allows Inflamax Research to continue to provide the best service possible in quality EEC clinical research”.
Brian Barney, President of Northern Air, echoed this positive outlook on the partnership, “Formalizing our relationship to become exclusive partners with Inflamax is the result of Inflamax and Northern Air Principals working together over many years. Inflamax is an innovator in clinical research and EEC technologies and Northern Air is a world leader in environmental control systems. Together, our companies will continue to lead further advancements.”
About Inflamax Research Inc.:
Inflamax conducts single and multi-centre Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax’s mobile EEC technology (mEEC™) systems which can be positioned globally, Inflamax has six fixed EECs, ranging in patient capacity from 25 to 100 patients at their headquarters in Toronto, Canada. Inflamax’s EECs have been validated for a variety of allergens and environmental conditions including ragweed, grass, dust mite, and tree allergens, and non-allergic provocateurs such as thermal shifts, fragrance, ozone and low humidity conditions such as those utilized in the study of dry eye syndrome.
About Northern Air Environmental Technologies Inc.:
Northern Air Environmental Technologies Inc. is a full service provider of turn-key environmental systems. Northern Air’s range of skills will take a project from raw concept, through detailed design, and construction, and provide clients with a single-sourced solution that truly achieves the overall performance goals o
Page: 1 2 3 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.2
. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.3
. Inflamax Research Appoints
Dr. Anne Marie Salapatek President & Chief Scientific Officer4
. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection5
. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials6
. Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research7
. Invitation to Register: Annual Defense Threat Reduction Agency Basic Research Technical Review8
. New Research On Stuttering Jul 2-3 At Arizona Symposium9
. UCSB researchers identify the mechanisms underlying salt-mediated behaviors in fruit flies10
. DNA Sequencing Market 2013 Developments & 2016 Product Forecasts in New Research Reports at ReportsnReports.com11
. David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research